How Much Does Coffee Actually Protect Your Liver? What a 13-Year, 350,000-Person Study Found

A landmark 2026 study of 354,957 adults tracked for 13 years found that drinking five or more cups of coffee per day was associated with a 32% lower risk of cirrhosis, a 47% lower risk of liver cancer, and a 42% lower risk of dying from liver disease compared with people who drink no coffee at all — making it one of the most comprehensive investigations into coffee and liver health ever conducted.

The study, led by researchers at Cedars-Sinai Health Sciences University in Los Angeles and published July 1, 2026, in Clinical Gastroenterology and Hepatology, drew on UK Biobank data and combined long-term health outcome tracking with liver MRI imaging and blood protein analysis — a multi-layered approach that distinguishes it from earlier, narrower research.

Before diving into the mechanisms and caveats, here is a snapshot of what the evidence shows across different intake levels and outcome types:

Coffee Intake	Cirrhosis Risk Reduction	Liver Cancer Risk Reduction	Liver-Related Death Risk Reduction
1–2 cups/day	Modest benefit observed	Modest benefit observed	Modest benefit observed
3–4 cups/day	Strongest association range	Strongest association range	Strongest association range
5+ cups/day	32% lower risk	47% lower risk	42% lower risk
Decaffeinated	Similar to caffeinated	Similar to caffeinated	Similar to caffeinated
With sugar/sweeteners	Benefit present but higher liver inflammation marker (icT1) observed	Benefit present	Benefit present

Source: Cedars-Sinai newsroom, Daily Coffee News

What exactly did the study measure, and why does its size matter?

The Cedars-Sinai study is an observational cohort analysis — meaning researchers tracked real-world behaviour and health outcomes over time without intervening or assigning participants to drink coffee. That distinction matters for interpreting the results, and the researchers are explicit about it.

What makes this study unusually solid is its scale and layered evidence. The 354,957 participants enrolled in the UK Biobank had no cirrhosis or liver cancer at the start. Over a median follow-up of 13 years, researchers linked their coffee-drinking habits to new diagnoses of cirrhosis, hepatocellular carcinoma (the most common form of liver cancer), and liver-related deaths — all tracked through linked health records.

The team went further than prior work. A subgroup of 28,961 participants underwent liver MRI scans, allowing researchers to measure liver fat, iron levels, fibrosis, and inflammation directly rather than inferring them from diagnoses. A separate subgroup of 44,633 participants had blood protein analyses, revealing which biological markers were higher or lower in coffee drinkers.

"Previous studies suggested that coffee might benefit the liver, but most were smaller or looked at only one piece of the puzzle," said Hyunseok Kim, MD, MPH, PhD, assistant professor of medicine at Cedars-Sinai and the study's corresponding author. "We followed hundreds of thousands of people for more than a decade and looked at their health outcomes along with liver MRI scans and blood protein analyses. Together, those findings help explain the biological mechanisms behind coffee's association with better liver health."

How does coffee actually affect the liver at a biological level?

This is where the 2026 study breaks new ground. Prior research established the association between coffee and liver health; this study provides some of the clearest biological evidence yet for why that association might exist.

The MRI findings showed that heavier coffee drinkers had measurably lower levels of liver fat, liver iron, fibrosis, and inflammation on imaging. These are not abstract statistical correlations — they are direct physical measurements of liver tissue condition. Blood protein analysis further showed that coffee drinkers had higher concentrations of proteins associated with healthy liver function and lower concentrations of proteins linked to scarring and immune activation.

Earlier research has pointed to several candidate mechanisms. Coffee contains more than 1,000 biologically active compounds, including caffeine, chlorogenic acids, kahweol, and cafestol. A review published in the Journal of Clinical and Experimental Hepatology notes that coffee consumption is associated with improvement in liver enzymes — specifically ALT, AST, and GGTP — particularly in individuals already at risk for liver disease, and that intake of more than two cups per day has been linked to lower incidence of fibrosis, cirrhosis, and hepatocellular carcinoma.

Caffeine metabolism is one piece of the puzzle. When the body breaks down caffeine, it produces paraxanthine, a compound that may slow the growth of scar tissue involved in fibrosis. Two other coffee compounds — kahweol and cafestol — have shown potential anti-cancer properties in laboratory settings, though their clinical significance in humans is still being worked out.

Chlorogenic acids, antioxidant compounds abundant in both caffeinated and decaffeinated coffee, are thought to reduce oxidative stress and inflammation in liver tissue. The fact that decaffeinated coffee showed similar protective associations in the 2026 study strongly suggests that caffeine is not the sole — or even primary — driver of the benefit. Other compounds in the coffee matrix appear to be doing meaningful work.

Researchers have not yet pinpointed exactly which compounds or biological pathways are responsible, and the picture is almost certainly more complex than any single ingredient. As The Educated Patient notes, coffee contains "hundreds of biologically active compounds, including caffeine, chlorogenic acids and diterpenes, that may reduce inflammation, oxidative stress and liver scarring."

Does it matter whether you drink caffeinated or decaffeinated coffee?

One of the most practically useful findings from the 2026 study is that both caffeinated and decaffeinated coffee showed similar protective associations with liver health. This is a meaningful result for people who avoid caffeine for medical reasons, sleep concerns, or personal preference.

Decaffeinated coffee has most — typically 97% or more — of its caffeine removed while retaining the bulk of other chemical compounds. The comparable liver benefits of decaf point researchers toward non-caffeine compounds as the primary active agents.

Earlier research supports this. A review in PMC noted that acids in coffee may work against the hepatitis B virus, and that decaf coffee could carry the same benefit. The 2026 Cedars-Sinai study adds large-scale, long-term outcome data to that picture.

For people who enjoy coffee but are sensitive to caffeine, this finding is reassuring: switching to decaf does not appear to forfeit the liver-protective associations. If you are interested in other caffeine-free options for general wellness, caffeine-free herbal teas serve different purposes and have their own evidence base, but they are not direct substitutes for coffee's specific liver-related compounds.

What about adding sugar or artificial sweeteners to your coffee?

This is one area where the 2026 study introduces a note of caution. Participants who added sugar or artificial sweeteners to their coffee had higher odds of elevated iron-corrected T1 (icT1) — an MRI marker associated with liver inflammation and fibrosis.

The researchers are careful not to overstate this finding. The study cannot establish whether those additives directly caused the elevated marker, or whether the finding reflects other lifestyle or dietary factors correlated with sweetener use. It is an association within an observational study, not a proven causal mechanism.

What it does suggest is that the liver benefits of coffee may be most cleanly observed in people who drink it unsweetened or with minimal additives. The Educated Patient's coverage of the study notes that "adding sugar or artificial sweeteners did not eliminate the benefit either, though the researchers noted that people who used additives showed slightly higher levels of a marker associated with liver inflammation."

The practical takeaway is modest: if you already drink coffee and are concerned about liver health, opting for unsweetened coffee where possible is a reasonable, low-effort adjustment. It is not a reason to stop drinking coffee with a splash of milk, and it is certainly not a reason to avoid coffee altogether.

How does this study compare with earlier coffee-liver research?

The 2026 Cedars-Sinai findings are consistent with — and extend — a growing body of evidence. Understanding the trajectory of this research matters, because it shows a field progressively building confidence in an association that was once considered speculative.

A 2021 UK Biobank study involving nearly half a million participants found that coffee drinkers had a 21% lower risk of chronic liver disease and a 49% lower risk of death from chronic liver disease, with peak risk reduction around three to four cups per day. That study was large, but it focused on chronic liver disease as a broad category rather than distinguishing between cirrhosis, liver cancer, and liver-related death as separate outcomes.

The 2026 study improves on that by disaggregating outcomes, adding MRI and blood protein data, and controlling for a wider range of variables including coffee type and additive use. The risk reductions it reports for specific outcomes — 32% for cirrhosis, 47% for liver cancer, 42% for liver-related death at five-plus cups — are higher than the 21% figure from 2021, but the two studies are measuring different things and should not be read as contradictory.

Earlier meta-analyses and reviews have also consistently found protective associations. A review published in the Journal of Clinical and Experimental Hepatology concluded that coffee intake of more than two cups per day in patients with pre-existing liver disease was associated with lower incidence of fibrosis and cirrhosis, lower hepatocellular carcinoma rates, and decreased mortality. The 2026 study extends this to a healthy population followed prospectively, which is methodologically stronger.

WebMD's summary of the broader evidence notes that in one study, two cups a day cut the odds of cirrhosis by 44%, and four cups a day lowered them by 65% — figures from older, smaller studies that are directionally consistent with the 2026 findings, even if the specific numbers differ.

Should you start drinking coffee specifically to protect your liver?

No — and the researchers behind the 2026 study are explicit on this point.

"Our findings support moderate coffee consumption for people who already enjoy and tolerate it well," said senior author Ju Dong Yang, MD, medical director of the Liver Cancer Program at Cedars-Sinai. "However, we would not recommend that someone begin drinking coffee solely for liver protection based on this study alone. Prevention should continue to focus on maintaining a healthy weight, limiting alcohol, exercising regularly, and managing blood sugar, blood pressure and cholesterol."

This is a standard and appropriate caveat for observational research. Because researchers observe outcomes without controlling the exposure, they cannot rule out confounding factors. Coffee drinkers may differ from non-drinkers in dozens of ways that affect liver health, and while large, well-designed studies like this one attempt to control for known confounders, residual confounding is always possible.

That said, the consistency of the association across multiple large studies, multiple outcome measures, multiple coffee types, and now multiple biological markers (MRI and blood proteins) does strengthen the plausibility of a genuine protective effect. The biological correlates being identified — reduced liver fat, lower iron accumulation, less fibrosis and inflammation — are not random noise. They are coherent with what we know about how liver disease progresses.

The practical position most evidence supports: if you already drink coffee and tolerate it well, you may be getting a meaningful liver health benefit as a side effect of your existing habit. If you do not drink coffee, the current evidence does not justify starting solely for liver protection — weight, alcohol intake, exercise, and metabolic health all have stronger and more direct evidence bases.

What does this mean for people with existing liver conditions?

The 2026 study enrolled participants who had no cirrhosis or liver cancer at baseline, so its findings speak most directly to prevention rather than treatment of established disease. Earlier research has examined coffee's role in people who already have liver conditions, and the picture there is also broadly positive.

The Journal of Clinical and Experimental Hepatology review found that coffee consumption was associated with slower progression of fibrosis and cirrhosis, lower hepatocellular carcinoma rates, and decreased mortality in people with pre-existing liver disease — including hepatitis B, hepatitis C, non-alcoholic fatty liver disease (NAFLD), and alcoholic liver disease. Moderate amounts, typically between one and three cups a day, may slow the progression of fibrosis, cirrhosis, and hepatitis B and C.

For people managing fatty liver disease specifically, coffee's apparent ability to reduce liver fat accumulation — as seen in the MRI subgroup of the 2026 study — is particularly relevant. Non-alcoholic fatty liver disease, the accumulation of excess fat in liver cells in people who drink little or no alcohol, is one of the most common liver conditions globally. If coffee genuinely reduces liver fat deposition, that is a meaningful finding for this population.

Anyone with a diagnosed liver condition should discuss coffee consumption with their hepatologist or gastroenterologist. Coffee is not a treatment, and individual circumstances — including medication interactions, tolerance, and underlying condition severity — vary considerably.

What are the limitations of this research?

Intellectual honesty requires acknowledging what this study cannot tell us.

First, it is observational. Researchers cannot randomly assign people to drink five cups of coffee a day for 13 years and compare them to a control group. The associations found are strong and consistent, but causation is not proven.

Second, the study population is drawn from the UK Biobank, which skews toward healthier, more health-conscious participants than the general population. Whether the findings generalise fully to other populations — including those with higher rates of liver disease risk factors — is uncertain.

Third, coffee consumption was self-reported at enrollment and may not accurately reflect intake over the full 13-year follow-up period. People's coffee habits change, and a single baseline measurement introduces measurement error.

Fourth, the finding about sugar and artificial sweeteners is intriguing but under-powered for firm conclusions. The researchers themselves note that the elevated icT1 marker in sweetener users could reflect other factors rather than a direct effect of the additives.

Fifth, while the study identifies biological correlates — lower liver fat, less fibrosis on MRI, different protein profiles — it does not establish the specific compounds or pathways responsible. That mechanistic gap means we cannot yet design a "liver-protective" coffee formulation or dose with precision.

What is the bottom line for everyday coffee drinkers?

The evidence from this 13-year, 354,957-person study — combined with the broader literature — paints a consistent picture: regular coffee consumption, at levels most people already drink (one to four cups per day), is associated with meaningfully lower risks of serious liver disease. The association appears for both caffeinated and decaffeinated coffee, across multiple outcome measures, and is now supported by direct biological evidence from MRI imaging and blood protein analysis.

The sweet spot in the data appears to be three to four cups per day, where protective associations are strongest without requiring the five-plus cups that most people would find impractical or uncomfortable. Benefits are detectable even at one to two cups daily.

Coffee is not a liver medicine. It does not replace the established pillars of liver disease prevention: maintaining a healthy weight, limiting alcohol, exercising regularly, and managing metabolic risk factors. But for the hundreds of millions of people who already drink coffee daily, this study adds to a growing body of evidence that their habit may be doing their liver a quiet, sustained favour.

If you are exploring other functional beverages for general wellness, herbal teas for digestion and immune-support blends serve different purposes and have their own evidence bases — but for liver-specific associations, the coffee data remains in a class of its own in terms of scale and consistency.